Develop a holistic GLP-1 strategy

An evidence-based approach to GLP-1 drugs helps you implement custom strategies that promote clinically appropriate use and consider affordability, long-term value and member health outcomes.

85%

Eighty-five percent of people who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for weight loss were no longer taking the drug after two years.

The evolution of GLP-1s

When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 use for weight loss by just 1% of an insured population would drive more than an additional $10 in costs PMPM, totaling 5% of a self-insured employer’s drug spend.² So it’s clear that having a strong GLP-1 strategy is an essential element of a successful pharmacy benefits program. 

Prime Therapeutics GLP-1 research: Year-2 cost of care is $4,200 higher for patients with obesity

Individuals without diabetes who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for obesity experienced an average of $4,206 higher cost of care in their second year compared to like members not taking a GLP-1 drug for obesity. The study also shows that across the obesity-related outcomes included in the study, no reduction in medical events was observed over the first two years of therapy.

Learn more

Real-world analysis of GLP-1 drugs

Demand for GLP-1 drugs for weight loss has increased, new data shows additional insights find low adherence and increased cost in first year.

Learn more

Prime continues to lead industry on GLP-1 research

Real-world, integrated data follows-up on previous insights and analytics. In fact, 1 in 7 stays on GLP-1 drugs for weight loss after two years.

Learn more

Pharmacy Friends

Pharmacy Friends is a podcast dedicated to bringing industry experts to the same table to talk about what is happening in pharmacy today, what is coming in the future, and most importantly, what it means to you. Listen to our episodes that focus on the hot topic of GLP1s and chronic weight management. 

Holistic solutions for weight management

More than 73.1% of adults in the United States are either overweight or obese. In addition to the health impact, obesity costs the health care system almost $173B per year. Prime’s clinical insights report outlines where we are today and how things are shaping up for the future, demystifying trends like GLP-1s and supporting a whole-person approach to sustainable weight management.

Next-level cardiometabolic support

Conditions like obesity, diabetes, hypertension and high cholesterol can compound if left unchecked, causing serious and costly health problems. KeepWell™ offers a personalized and effective path to wellness for your members, driving better outcomes across the cardiometabolic spectrum
Login Portals
Compliance / Legal
Careers
© 2024 Prime Therapeutics LLC